ProNaGen: Engineering of Recombinant Protein Nanosheet-Based Bioemulsions for Next Generation Bioprocessing and Biomanufacturing

细胞疗法和基于细胞的体外模型民主化的一个重要障碍仍然是我们扩大规模并使细胞制造和处理自动化的能力有限。虽然固体和水凝胶微载体和磁性微粒已经显示出解决这一缺陷的一些前景，但它们仍然难以加工，并与细胞产品分离，导致产生的细胞团可能受到污染，并与高昂的成本相关。为贴壁细胞的培养和加工设计负担得起的、可扩展的和符合监管要求的平台，同时避免对固体基质和微载体的依赖，仍然是细胞制造的关键，并将对相关生物技术市场的持续增长产生重要影响。为了避免细胞产品受到微塑料或微粒的污染，简化生物加工并降低相关成本，生物乳剂最近被提出为有吸引力的替代品。尽管它们的性能已经在越来越多的案例中得到证明，但目前的蛋白质和聚合物纳米片技术依赖于蛋白质和材料，这些蛋白质和材料在再生医学(包括细胞植入)中的应用存在遵守法规的风险。

An important hurdle to the democratisation of cell therapies and cell-based in vitro models remains our limited ability to scale up and automate cell manufacturing and processing. Whilst solid and hydrogel microcarriers and magnetic microparticles have shown some promise to tackle this pitfall, they remain difficult to process and separate from cell products, lead to potential contamination of the cell mass generated and are associated with high costs. The design of affordable, scalable and regulatory-ready platforms for the culture and processing of adherent cells, yet by-passing the reliance on solid substrates and microcarriers, remains essential for cell manufacturing and will have an important impact on the sustained growth of associated biotech markets. To bypass the contamination of cell products with microplastics or particles, simplify bioprocessing and reduce associated costs, bioemulsions have recently been proposed as attractive alternatives. Although their performance has been demonstrated in a growing number of cases, current protein and polymer nanosheet technologies rely on protein and materials that present a risk for regulatory compliance, for applications in regenerative medicine (including for cell implantation).